Roberto Iacovelli: Tom Powles represented NIAGARA results for perioperative therapy of MIBC at ESMOAsia24
Roberto Iacovelli, Medical oncologist at Fondazione Policlinico Gemelli IRCCS in Rome, shared a post on X:
“Tom Powles re-presented NIAGARA results for perioperative therapy of MIBC at ESMOAsia24.
Dr. Rajappa shared an excellent discussion on why this is now the standard of care which can also flow to Asia.”
Petros Grivas, Clinical Director of the Genitourinary Cancers Program at the University of Washington, also reshared the post:
“Fantastic discussion by Dr. Rajappa on Tom Powles brilliant presentation of NIAGARA.
Despite low use of adjuvant IO in control arm and variable access to salvage Treatment, significant OS/EFS and lack of notable toxicity->new SOC in peri-op MIBC.”
Dr. Roberto Iacovelli, is a medical oncologist at Fondazione Policlinico Gemelli IRCCS in Rome, Italy. With a focus on genitourinary cancers, his research focuses on metastatic renal cell carcinoma, prostate, and bladder cancer, exploring predictive factors and therapy sequencing. Dr. Iacovelli’s contributions include over 150 publications in peer-reviewed journals and numerous awards for his work, including the ASCO Cancer Foundation Merit Award in 2011.
Dr. Petros Grivas, a board-certified medical oncologist, serves as Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance. He’s an Associate Professor at the Dept. of Medicine and Associate Member at Fred Hutchinson Cancer Research Center since January 2018. With extensive training and experience, he’s led clinical trials, contributing to FDA approvals for bladder/urothelial cancer treatments.
More posts featuring Roberto Iacovelli.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023